KDR and ovarian cancer: After evaluation of efficiency of this peptide vaccine on inhibition of VEGFR2 signaling pathway (32), Wang et al. used these synthetic peptide vaccines in murine ovarian cancer model, and the development of high titers of antibody against synthetic peptides was in line with inhibition of angiogenesis in primary tumor models (33).